Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524297 | 0.73 | HTT (0.62) | MAPK1HTTPOLBKDM4EMAPT | |
| SCHEMBL13184345 | 0.72 | MAPK1 (0.48) | MAPK1HTTPOLBKDM4EFGFR1 | |
| SCHEMBL311147 | 0.70 | MAPK1 (0.52) | MAPK1HTTPOLBKDM4EFGFR1 | |
| SCHEMBL3419279 | 0.69 | HTT (0.88) | HTTPOLBKDM4EMAPTNPSR1 | |
| SCHEMBL3417306 | 0.69 | HTT (0.73) | HTTPOLBFGFR1ALDH1A1TDP1 | |
| SCHEMBL30402227 | 0.69 | HTT (0.88) | HTTPOLBKDM4EMAPTNPSR1 | |
| SCHEMBL29463931 | 0.69 | HTT (0.51) | MAPK1HTTPOLBFGFR1TDP1 | |
| SCHEMBL10094729 | 0.69 | MAPK1 (0.59) | MAPK1HTTPOLBKDM4ENPSR1 | |
| SCHEMBL19477580 | 0.69 | HTT (0.51) | MAPK1HTTPOLBFGFR1TDP1 | |
| SCHEMBL17212385 | 0.69 | ACP1 (0.54) | MAPK1HTTPOLBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | MAPK1 1185/4885HTT 1177/4885POLB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.